ReferenceID 4472
Preclinical Investigation of Alpinetin in the Treatment of Cancer-Induced Cachexia via Activating PPARγ
Front Pharmacol
The ongoing loss of skeletal muscle is a central event of cancer cachexia, and its consequences include adverse effects on patient's quality of life and survival. Alpinetin (Alp), a natural plant-derived flavonoid obtain
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 4472
- Evidence Id
- 21062
- Core Evidence Id
- 21062
- Source Reference Id
- 2230
- Herb2 Reference Id
- HBREF003027
- Subject Paper Key
- HBIN015751_34093209
- Pubmed Id
- 34093209
- Doi
- 10.3389/fphar.2021.687491
- Paper Title
- Preclinical Investigation of Alpinetin in the Treatment of Cancer-Induced Cachexia via Activating PPARγ
- Paper Abstract
- The ongoing loss of skeletal muscle is a central event of cancer cachexia, and its consequences include adverse effects on patient's quality of life and survival. Alpinetin (Alp), a natural plant-derived flavonoid obtained from Alpinia katsumadai Hayata, has been reported to possess potent anti-inflammatory and antitumor activities. This study aimed to explore the therapeutic effect and underlying mechanism of Alp in the prevention of cancer cachexia. We found that Alp (25-100 muM) dose-dependently attenuated Lewis lung carcinoma-conditioned medium-induced C2C12 myotube atrophy and reduced expression of the E3 ligases Atrogin-1 and MuRF1. Moreover, Alp administration markedly improved vital features of cancer cachexia in vivo with visible reduction of the loss of tumor-free body weight and wasting of multiple tissues, including skeletal muscle, epididymal fat, and decreased expression of Atrogin-1 and MuRF1 in cachectic muscle. Alp suppressed the elevated spleen weight and serum concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, and IL-6. Further, Alp treatment remained protective against cancer cachexia in the advanced stage of tumor growth. Molecular docking results suggested that Alp was docked into the active site of PPARgamma with the docking score of -7.6 kcal/mol, forming a hydrogen bond interaction with PPARgamma protein amino acid residue HIS449 with a bond length of 3.3 A. Mechanism analysis revealed that Alp activated PPARgamma, resulting in the downregulated phosphorylation of NF-kappaB and STAT3 in vitro and in vivo. PPARgamma inhibition induced by GW9662 notably attenuated the improvement of Alp on the above cachexia phenomenon, indicating that PPARgamma activation mediated the therapeutic effect of Alp. These findings suggested that Alp might be a potential therapeutic candidate against cancer cachexia.
- Journal
- Front Pharmacol
- Publish Year
- 2021
- Experiment Subject
- patient
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Cancer Cachexia; Tumor
- Paper Title Cn
- Paper Title En
- Preclinical Investigation of Alpinetin in the Treatment of Cancer-Induced Cachexia via Activating PPARγ
- Bilingual Status
- semi_complete